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Abstract
Background: Up to 50% of medicines are not used as intended, resulting in poor health and economic outcomes.
Medicines optimisation is ‘a person-centred approach to safe and effective medicines use, to ensure people obtain
the best possible outcomes from their medicines’. The purpose of this exercise was to co-produce a prioritised
research agenda for medicines optimisation using a multi-stakeholder (patient, researcher, public and health
professionals) approach.
Methods: A three-stage, multiple method process was used including: generation of preliminary research questions
(Stage 1) using a modified Nominal Group Technique; electronic consultation and ranking with a wider multi-
stakeholder group (Stage 2); a face-to-face, one-day consensus meeting involving representatives from all
stakeholder groups (Stage 3).
Results: In total, 92 research questions were identified during Stages 1 and 2 and ranked in order of priority during
stage 3. Questions were categorised into four areas: ‘Patient Concerns’ [e.g. is there a shared decision (with patients)
about using each medicine?], ‘Polypharmacy’ [e.g. how to design health services to cope with the challenge of
multiple medicines use?], ‘Non-Medical Prescribing’ [e.g. how can the contribution of non-medical prescribers be
optimised in primary care?], and ‘Deprescribing’ [e.g. what support is needed by prescribers to deprescribe?]. A
significant number of the 92 questions were generated by Patient and Public Involvement representatives, which
demonstrates the importance of including this stakeholder group when identifying research priorities.
Conclusions: A wide range of research questions was generated reflecting concerns which affect patients,
practitioners, the health service, as well the ethical and philosophical aspects of the prescribing and deprescribing
of medicines. These questions should be used to set future research agendas and funding commissions.
Keywords: Medicines optimisation, Polypharmacy, Deprescribing, Patient concerns, Non-medical prescribing,
Nominal group technique
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Background
Globally, medicines are the most commonly used
healthcare intervention [1]. In the United Kingdom
(UK), for example, over 1 billion prescription items
are dispensed annually in the community, many for
chronic health conditions [2]. Up to 50% of medicines
are not used as intended [3] and, as a result, health
outcomes are sub-optimal. Both over- and under- use
of medicines leads to diminished benefits, greater
costs and increased harms [3], and is viewed by the
World Health Organisation (WHO) as a global pa-
tient safety problem [4].
Medicines optimisation, ‘a person-centred approach
to safe and effective medicines use, to ensure people
obtain the best possible outcomes from their medi-
cines’ [5], focuses on ensuring that the patient de-
rives the most benefit from their medicines, and
requires a holistic approach and an effective partner-
ship between health professionals and patients [5, 6].
It also includes deprescribing, i.e. the process of
withdrawing a patient’s medicine to improve health
or mitigate against possible adverse side effects [7,
8]. Medicines optimisation is of relevance and im-
portance to a wide range of stakeholders including
patients, the public, healthcare professionals, health
service commissioners and policymakers. Achieving
the optimal use of medicines is complex due to com-
peting priorities and agendas of different stakeholders
[9]. The development of relevant policy requires an
expansion of the evidence base, which reflects the
needs of all stakeholders. This is apposite as medi-
cines optimisation is typically under-represented in
current models of care [10].
Involving patients and their advocates in the co-
production of health services and research is becom-
ing more commonplace [11]. Co-production leads to
differentiated services and choice, increased respon-
siveness to changing needs, and reduced waste and
costs [12]. It emphasises the contribution that all
stakeholders can make as initiators or recipients of
the service delivery process [12, 13] and is based on
egalitarian relationships between experts and lay
people, using a process of open exchange and partici-
pation [14]. The inclusion of the public and other
stakeholders in research agenda setting is increasing
[15–17] but until now, has not included medicines
optimisation. The aim of this exercise was to adopt a
multi-stakeholder approach to the co-production of a
prioritised research agenda for medicines optimisa-
tion. In so doing, the agenda could be used to inform
future funding initiatives and activities. This process
was undertaken as a GW4 Alliance [18] research ini-
tiative; a collaboration between the Universities of
Bath, Bristol, Cardiff and Exeter.
Method
Study design
The prioritisation process involved multiple stages and
methods. These included identification of a broad range
of stakeholders, face-to-face meetings to generate initial
research questions, and a one-day workshop to prioritise
the research questions generated. The overall process
was based on a modified Nominal Group Technique
(NGT) [19–21]. The NGT is usually conducted with
homogenous groups [22].
Stage 1: generation of preliminary research questions
The first stage involved the identification of key stake-
holders within the GW4 Alliance institutions, e.g. aca-
demics with expertise in pharmacy and pharmacology,
medical and other healthcare professionals, and patient
and public involvement representatives i.e. health service
users and organisational representatives. In August 2018,
a face-to-face stakeholder meeting was convened (by the
corresponding author), to undertake a modified Nominal
Group Technique (NGT) [19–21]. Participants were
provided background information and asked to address
thequestion: ‘What are the priority topics/areas that
need to be addressed so that medicines optimisation can
be realised?’. During the meeting, participants, including
the research team, were encouraged to generate as many
questions as possible in response to the research ques-
tion; these were recorded as individual written responses
and collated on flip-charts. No discussion was permitted
until the generation process was complete. Discussion
then followed for the purpose of clarification of ques-
tions, removal of duplicates and the identification of
common themes. Following the meeting, the questions
were reviewed by the research team and refined to pro-
duce a distilled list of research questions for consider-
ation in Stage 2. Each question was assigned to one of
four categories that reflected common themes: ‘patient
concerns’, ‘polypharmacy’, ‘non-medical prescribing’
(NMP), and ‘deprescribing.
Stage 2: consultation with wider stakeholder group
The purpose of Stage 2 was to seek input from a wider
stakeholder group regarding the original research ques-
tions identified in Stage 1. In addition to Stage 1 partici-
pants, an email invitation was sent to 80 individuals
identified from relevant literature and policy documents
and via the professional networks of the core research
team and which included a wide range of local, regional,
national, and international stakeholders (e.g. pharma-
cists, academic pharmacists, physicians, National Health
Service (NHS) Trust directors, patients, physicians,
health workers, and advocacy organisations (including
Age UK and the Patients’ Association)). All questions
from Stage 1 were presented in a document, using the
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four categories, and emailed to all prospective partici-
pants. The task for participants was to rank the Stage 1
questions according to their perceived importance, and
to add new questions from their own ideas/experiences.
For each original question, a mean rank was calculated
using the Excel rank function. Additional questions sug-
gested by participants were sense checked with duplicate
questions removed or combined and then assigned to
one of the original four question categories according to
its content.
Stage 3: final prioritisation
Stage 3 comprised a one-day prioritisation workshop in
November 2018, held on University of Bath campus and
facilitated the lead author (MCW). All respondents in
Stages 1 and 2 were invited. Participants and the re-
search team were purposively assigned to one of four
groups comprising eight individuals, to ensure that each
group included a range of participants, e.g. at least one
lay representative, and representatives from each stake-
holder group.
The research questions in each of the four categories
were discussed within each group with each category be-
ing assigned 45-min discussion session. Discussion in-
cluded the opportunity to reflect on the mean rank of
questions from Stage 1.
Following discussion session, the participants rated the
importance of each question. TurningPoint software was
used, which facilitates live polling and as well as the cur-
ation and simple statistical analysis of results [23]. Each
question was presented alongside a Likert scale, ranging
from one (‘extremely important’), to seven (‘extremely
unimportant’). Participants rated each question inde-
pendently. The process was then repeated for three
remaining categories of research questions.
Following the meeting, the questions were presented
in ordered rank to derive a definitive list of prioritised
research questions (Additional file 1; a list of all 92 ques-
tions alongside their rank, how they were rated by PPIs
and non-PPIs, and the percentage of ‘extremely import-
ant’ and ‘important’ ratings).
Patient and public participants received a participation
fee and their travel expenses were reimbursed. Non-PPI
participants had their travel expenses reimbursed if re-
quested, but received no additional payment for their
involvement.
Ethical approval and consent
Ethical approval was not required for this study (con-
firmed by the Ethics Officer of the Department of Phar-
macy and Pharmacology, University of Bath). As such,
signed consent was not sought from any participant.
Participation in, and completion of, each stage was ac-
cepted as participants’ consent to participate.
Data analysis
A Borda count [24, 25] was used to rank the order of
questions prioritised in Stage 3, where the Likert rating
‘extremely important’ was given a weighting of 7, ‘im-
portant’ a weighting of 6 and so forth, to ‘extremely un-
important’ weighted as 1. Following weighting, the
number of times a question was rated as ‘extremely im-
portant’ was combined with the number of times it was
rated as ‘important’ etc. For example, if 19 people rated
a question as ‘extremely important’, eight rated it as ‘im-
portant’, and five rated it ‘somewhat important’, then its
overall weighted score would be (19 × 7) + (8 × 6) + (5 ×
5) = 206. Weighted question totals were subsequently
ranked according to median score.
Using the process described above, the top five ques-
tions prioritised in each topic area by PPI participants
were compared with the rank given to the selected ques-
tions by all other participants (designated as non-PPI).
The purpose of this comparison was to determine
whether substantial differences existed in the type of
question that both types of participants prioritised. Such
information provides greater insight into the heterogen-
eity of different stakeholder types. During ranking exer-
cises, participants often rank their most and least
favourite choices, based for example on familiarity with
concepts, therefore middle rankings may reflect more ar-
bitrary or indifferent choices [26]. As such, the five high-
est ranked questions are discussed as this number will
likely capture the broad range of what participants have
actively considered as most important, while allowing
sufficient coverage of the overall question set.
Results
Stage 1: generation of preliminary research questions
Nineteen individuals participated. Of these, the majority
were academics, eight of whom had a pharmacy back-
ground (Fig. 1), as well as two GPs and two PPI repre-
sentatives. Thirty questions were generated and grouped
into four categories. All five questions pertaining to pa-
tient concerns were generated by PPI representatives.
Stage 2: consultation with wider stakeholder group
Forty stakeholders, including those from Stage 1, partici-
pated in Stage 2 (Fig. 1); two Stage 1 participants did not
participate in any later stages of this process. Approxi-
mately one third of participants were academics and four
participants had a medical background. In total, 62 new
questions were generated across the four categories: pa-
tient concerns (13), polypharmacy (13), non-medical
prescribing (14), and deprescribing (22). Of these, 28
were generated by PPI representatives. All the additional
questions nominally reflected the four categories. Four
suggestions were omitted due to ambiguity of meaning
e.g. “Need to do more about process”. Some questions,
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reflected more than one category. For example, “How is
deprescribing, polypharmacy, etc undertaken by NMPs?”.
These questions were assigned to the category deemed
most relevant to their content.
Stage 3: final prioritisation
In total, 32 of the 40 Stage 2 participants participated in
the Stage 3 meeting, comprising academic pharmacists
(n = 9), pharmacists including a regional deputy director
of the medicines information service and an NHS Trust
regional director of pharmacy (n = 9), PPI representatives
(n = 7), academic researchers (n = 5), and GPs (n = 2).
Over half of the participants provided a rating of ‘ex-
tremely important’ or ‘important’ for 13 of 22 patient
concerns questions, 14 of 28 polypharmacy questions, 7
of 17 non-medical prescriber questions, and 15 of 25
deprescribing questions. Two questions from the poly-
pharmacy category, relating to the status of theory and a
specific intervention tool, received a rating of ‘unimport-
ant’ or ‘extremely unimportant’ from just under a third
of participants. No other question in any category re-
ceived comparably negative ratings. In all categories, rat-
ings were skewed toward the positive end of the scale;
only one question in the category of polypharmacy dem-
onstrated polarisation, i.e. equal numbers of positive and
negative ratings. This question pertained to whether
clusters of co-morbidities are ‘more important’ than the
total number of co-morbidities.
Of the top 20 items identified across the four categor-
ies (i.e. five per category) 10 had been identified by the
wider stakeholder group during Stage 2; five questions
received an ‘extremely important’ or ‘important’ rating
from at least three-quarters of participants (Table 1). All
Stage 3 questions are presented in Additional file 1.
The comparison of PPI versus non-PPI results demon-
strates variation across the different types of participants
(Table 2). Only nine of the 20 highest ranked questions
by PPI participants were ranked highly by the non-PPI
participants.
The greatest similarities between the two types of par-
ticipants were in the ‘patient concerns ‘category, where
four of the top five questions were mutually identified as
priorities.
Discussion
To our knowledge, this is the first report of a multi-
stakeholder approach to the development and prioritisa-
tion of research questions associated with medicines op-
timisation. Similar processes are used by the James Lind
Alliance [27]. The current exercise adopted a systematic
Fig. 1 The identification and prioritisation of medicines optimisation research questions: numbers of participants and questions generated
by stage
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approach that incorporated the opinions of a wide range
of stakeholders using participatory methods. The value
of these stakeholders, rather than limiting the process to
academic researchers and the literature, was illustrated
by the additional 62 questions that were identified dur-
ing Stage 2 as a result of including the extended stake-
holder group, as well as the comparison of PPI and non-
PPI priorities. Ten of the top 20 questions were identi-
fied by PPI; i.e. indicating the importance of including
these stakeholders. Our results illustrate the importance
of patient and public participants to inform research and
guideline development in relation to medicines optimisa-
tion, as recommended by an earlier review [28]. The pri-
orities identified by this process could be used by:
research funders to inform future research funding ini-
tiatives; researchers to identify and address priorities in
medicines optimisation research; PPI organisations to
lobby for change and promote awareness; and health
professionals to consider in terms of their medicines op-
timisation practice. Many of these priorities are likely to
be of relevance to the international community despite
being generated in the UK and reflect the aforemen-
tioned WHO global patient safety concern.
Several of the high priority questions reflected the ex-
tent to which patients’ views and experiences are consid-
ered during medication reviews. Few tools exist for
eliciting patient priorities and preferences during consul-
tations, including medication reviews [29]. As such, this
service might benefit from the introduction of a com-
mon framework built on equity, confidence, and percep-
tions of acceptance [30], for defining and classifying
patient-mediated interventions. Most of the questions
associated with medication reviews related to ‘structural’
elements, i.e. what constitutes a ‘good’ review, and when
is the ‘right’ time to undertake a review. The challenge
for future work comes from operationalising these
Table 2 Top 5 questions by topic and PPI rank, compared with non-PPI rank




Is there a shared decision (with patients) about using each medicine? 1 2
How are medication reviews by different healthcare professionals integrated? 2 5
To what extent are patients’ views and experiences considered during medication reviews? 3a 1
What are patients’ perspectives and experiences of non-medical prescribers, and does this vary according
to different professional groups and different patient groups?
3b 10
How can communication relevant to medication reviews be enhanced across and within sectors? 5 3
Polypharmacy PPI rank Non-PPI rank
To what extent should polypharmacy involve patients’ views and preferences in shared decision-making? 1 5
What can patients teach health care professionals about the burden of polypharmacy and coping (or not) mechanisms? 2 11
Which patients should be targeted by polypharmacy medication reviews, where and when? 3 7
What are the key components of a good, person-centred, holistic, polypharmacy medication review? 4 6
If we undertake a polypharmacy medication review well with the right person at the right time, what happens to the
patient (i.e. are their outcomes better, does their ‘quality of life’ improve etc.)?
5 2
Non-medical Prescribing PPI rank Non-PPI rank
How can we optimise the contribution of non-medical prescribers to primary care? 1 1
How can we raise patient awareness of these ‘new’ prescribers? 2 10
What is the role of the NMP in medicines reviews (e.g. in specialist areas such as rheumatology and type of NMP e.g.
pharmacist, nurse)?
3a 6
How can non-medical prescribers optimise medicines use in vulnerable patient populations e.g. drug misusers,
individuals with mental illness?
3b 13
How is deprescribing, polypharmacy, etc. undertaken by non-medical prescribers? 5 2
Deprescribing PPI rank Non-PPI rank
How can we empower patients to take a more active role in self-management and self-monitoring of multiple
long-term conditions, including deprescribing?
1 2
Should all ‘prescribing’ guidelines include recommendations to deprescribe, and if so how? 2 9
How can GPs and non-medical prescribers be assisted in dealing with deprescribing of medicines originally prescribed
by hospital consultants?
3a 9
Does providing full access to medical records enable more effective collaborative deprescribing decisions? 3b 8
How can pharmacological and holistic therapies be merged? E.g. deprescribing of antidepressants. 3c 18
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questions in objective, less value-laden terminology. This
was also reflected with the prioritisation of questions re-
garding polypharmacy – for example, the nature of in-
formation and education that the patient would require
to enable them to engage and have ownership of their
medication management.
Polypharmacy is of increasing relevance due to the
ageing population and the increasing number of people
receiving multiple medicines [2]. The top priorities
around polypharmacy identified in the present exercise
reflect the challenge of how best to involve patients in
decision making, especially in relation to medication re-
views, and how primary care is best engineered to ensure
their effectiveness.
In the UK, a range of non-medical health professionals
can prescribe medicines for patient [31]. The growth in
numbers of non-medical prescribers reflects the need to
mitigate increasing demands on the NHS [32]. The abil-
ity to prescribe has the potential to enhance the roles of
health care professionals and improve patient care by fa-
cilitating treatment provision in settings more accessible
to patients and possibly in a more timely manner [33].
The top five research questions in the NMP category in-
cluded the need to raise patient awareness of NMPs and
the extent to which NMP training provides practitioners
with the confidence to address complex polypharmacy
and deprescribing issues [34]. It has been suggested that
educational programmes for NMPs would benefit from
considering how best to maintain the currency of practi-
tioners’ knowledge [35], and that education aimed at the
public may be warranted, to address concerns and lim-
ited awareness with regard to the diagnostic skills and
status of NMPs [36].
The top-ranked ‘Deprescribing’ priority was “how to
empower patients to take a more active role in self-
management and self-monitoring of multiple long-term
conditions, including deprescribing?”, which was were
ranked ‘extremely important’ or ‘important’ by at least
three-quarters of participants, indicating a convergence
towards the desire for a broad culture shift i.e. consulta-
tions which reflect a more person-centered approach (a
core component of medicines optimisation), whereby pa-
tient perspectives are an integral part of the decision-
making process. Challenges associated with deprescribing
include how it is defined, whether it is safe, and how these
aspects are communicated to patients and health care pro-
fessionals alike [37]. This reflects a desire to adopt a holis-
tic approach to medicines optimisation, whereby patient
perspectives and values are central to the consultation
process, teams are inherently multidisciplinary, and where
the general perspectives as well as complexities of individ-
ual cases can be addressed [38–40].
The PPI research infrastructure has existed for over a
decade [41] and the importance of PPI in this
prioritisation exercise was reinforced by the many differ-
ences between their views and those of the non-PPI par-
ticipants [42]. Given that patient involvement in
healthcare decision-making can lead to better affective,
cognitive and health outcomes [43, 44], the value of in-
volving patients in the entire research process is implicit
in the top-ranked ‘patient concerns’, ‘Is there a shared
decision (with patients) about using each medicine?’
The third WHO Global Patient Safety Challenge,
Medication Without Harm, identified medication safety as
a priority [45]. A separate consensus exercise identified
the need to adopt technology to enhance medication
safety, and to develop guidelines and standard operating
procedures for high-risk patients, medications and con-
texts [46]. Within this current prioritisation exercise, it
was seldom stated explicitly medication safety but was im-
plicit in many questions. For example, ‘Patient concerns’
‘What are the advantages and disadvantages of online
pharmacy services in relation to access to medicines and
safety, patient experience, out-of-pocket expenses, informa-
tion provision?’ (rank 19), and ‘Deprescribing’ ‘Where are
the gaps in education and safety (about deprescribing) and
how these can be addressed is key to ensuring deprescribing
is safe and effective?’ (rank 4). This observation may reflect
the wording of the original NGT question and that the
subsequent apportioning of questions across the four cat-
egories decreased the salience of ‘safety’. As such, prior-
ities identified in the current exercise may differ
substantially from global priorities where, for example,
medicine safety is a recognised priority [47].
Strengths and limitations
A strength of this prioritisation exercise was the repre-
sentation at each stage of different stakeholder groups
(including PPI, pharmacists, and GPs) to ensure that
their different perspectives and experiences were repre-
sented throughout the process. This is likely to have im-
proved the relevance and real-world value of the
research outcomes, as well as the validity and reliability
of the findings [48]. Conversely, however, the high pro-
portion of pharmacist participants could have influenced
the results although the overall findings suggest that this
did not occur. If this approach was repeated with a wider
range of stakeholders, e.g. nurses and other NMPs and
health professionals, different priorities could have been
generated. Similarly, if repeated at a different time, the
outcomes could be influenced by high profile health
concerns e.g. COVID-19. An additional limitation relates
to the Stage 3 procedure of aggregating ratings into an
overall rank. Ascribing a score to each rating and then
summing the scores for a set of ratings by any one indi-
vidual may produce the same magnitude of outcome
from quite different sets of ratings. The Borda count
employed in Stage 3 overcomes this to some degree in
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that it takes all the rating preferences into account by at-
tributing weighted scores to each rating. However, this
still assumes that scores are interval in nature and does
not take into account the actual ‘attitude’ that the re-
spondent may have towards the question content [49].
Nonetheless, to test whether different scoring ap-
proaches significantly altered the nature of rankings, dif-
ferent methods of analysis were explored. For example,
given that ratings were skewed toward positive assess-
ments, rankings were constructed based on aggregates of
only ‘extremely important’ and ‘important’ ratings. While
this did not affect overall ranks substantially, it was de-
cided that a full Borda count that incorporated all rat-
ings was more apposite in that it maintained the full
range of perspectives from all participants.
Conclusions
We illustrate the value of co-producing a prioritised re-
search agenda for medicines optimisation using a multi-
stakeholder approach. Hence, the results and priorities
identified are relevant for clinicians, researchers, funding
bodies, and policy makers, in terms of the future re-
search agenda. Moreover, the results demonstrate the
importance and value of adopting an inclusive approach
with agenda-setting for health care.
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